NEW YORK, December 12, 2016 /PRNewswire/ --
Stock-Callers.com reviews the most recent performances of four Biotech equities which are: Mast Therapeutics Inc. (NYSEMKT: MSTX), Array BioPharma Inc. (NASDAQ: ARRY), Opko Health Inc. (NASDAQ: OPK), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). These companies belong to the Healthcare sector which outpaced other sectors during the session last Friday, December 09th, 2016. As per an article on the NASDAQ, the NYSE Health Care Index posted a 1.5% advance, while shares of health care companies in the S&P 500 rose 1.2% as a group. Learn more about these stocks by downloading their free research reports in PDF format at:
Last Friday at the close, shares in San Diego, California headquartered Mast Therapeutics Inc. ended 2.61% higher at $0.12. The stock recorded a trading volume of 51.36 million shares, which was above its three months average volume of 10.59 million shares. The Company's shares have surged 74.43% in the last one month. The stock is trading above its 50-day moving average by 40.43%. Furthermore, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have a Relative Strength Index (RSI) of 72.53.
On December 06th 2016, Mast Therapeutics reported that the first patient has been enrolled in an investigator-sponsored Phase 2 study of the Company's lead product candidate, AIR001, for the treatment of heart failure with preserved ejection fraction (HFpEF). The Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF study will evaluate AIR001's potential to improve the clinical responses to exercise training in individuals with HFpEF Sign up and read the free research report on MSTX at:
Boulder, Colorado headquartered Array BioPharma Inc.'s stock finished Friday's session 0.80% lower at $8.66 with a total trading volume of 4.59 million shares. The Company's shares have advanced 33.03% in the last one month, 139.89% over the previous three months, and 105.21% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 25.06% and 102.06%, respectively. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia/Pacific, have an RSI of 69.31. The complimentary research report on ARRY can be downloaded at:
Shares in Miami, Florida headquartered Opko Health Inc. ended the session 1.48% higher at $10.97 with a total trading volume of 2.66 million shares. The stock has gained 14.51% in the past month, 10.92% over the previous three months, and 9.15% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 9.57% and 8.92%, respectively. Moreover, shares of Opko Health, which engages in the discovery, development, and commercialization of novel and proprietary technologies in the US, Ireland, Chile, Spain, Israel, and Mexico, have an RSI of 60.60.
On November 23rd, 2016 OPKO Health announced that it will commence shipments of RAYALDEE™ (calcifediol) extended-release capsules to distributors in the US on November 29th, 2016. RAYALDEE was approved by the US FDA on June 17th, 2016. Register for free on Stock-Callers.com and access the latest report on OPK at:
Cambridge, Massachusetts headquartered Merrimack Pharmaceuticals Inc.'s stock recorded a trading volume of 2.21 million shares, and closed 2.37% higher at $5.61. The Company's shares have gained 18.86% in the previous three months. The stock is trading 0.55% below its 50-day moving average. Additionally, shares of Merrimack Pharma, which engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have an RSI of 48.93.
On November 09th, 2016, Merrimack reported that product revenues from the commercial sale of ONIVYDE, net of discounts, allowances and reserves, were $14.5 million for Q3 2016, up 13% compared to $12.9 million for Q2 2016. License and collaboration revenues were $12.4 million for Q3 2016 compared to $19.3 million for Q2 2016. Net loss attributable to Merrimack for Q3 2016 was $30.1 million, or $0.23 per share, compared to a net loss attributable to Merrimack of $50.8 million, or $0.40 per share, for Q2 2016. Get free access to your research report on MACK at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA